Search Results

ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc., its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

ARTMS Inc. is pleased to announce the production of zirconium-89 oxalate using a low energy medical cyclotron in a US based commercial nuclear pharmacy.

ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the submission of a Type 1 Master File with the Health Products & Food Branch, Health Canada (HC) for the production of gallium-68 (Ga-68).

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which analysts expect will help the pharma expand its production capacity.

ARTMS Inc. (ARTMS) is pleased to announce the submission of a Drug Master File (DMF) to the FDA for the high-volume production of Gallium-68 (68Ga) with ARTMS’ solid target technology in combination with a medical cyclotron

ARTMS Inc. is pleased to announce the production of Ga-68 Chloride using a medical cyclotron in a US based commercial nuclear pharmacy.